My ePortfolio Register   

AACR 2014 /
Phase I trial shows the benefits of OTX015 in treating blood cancer

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 2157

Dr Esteban Cvitkovic - Oncoethix, Lausanne, Switzerland

At a press conference during AACR 2014, Dr Cvitkovic presents the findings of his phase I trial which involved patients with a variety of haematological cancers being treated with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence